ESMO 2023 | Multicolor immunofluorescence to predict melanoma immunotherapy responses

Marco Donia, MD, PhD, Copenhagen University Hospital, Herlev, Denmark, discusses studies presented at the European Society for Medical Oncology (ESMO) 2023 Congress that have used complex multicolor immunofluorescence techniques to stratify patients who are unlikely to respond to treatment with PD-1 inhibitors. These techniques were also used to assess the likelihood of patients experiencing side effects whilst receiving the treatment with high accuracy. This interview took place at the ESMO 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.